A Phase 1/2 interventional study of Donor Hematopoietic Stem and Progenitor Cell Infusion in Liver Transplantation, Immune Tolerance and Immune Tolerance/Drug Effects, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by University of California, Los Angeles · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in End Stage Liver Disease with a site in United States — 9 open to participants now, 15 under way, none of them phase 3. End Stage Liver Disease · United States.
Among the 66 studies in End Stage Liver Disease with a site in United States, this one is the 40th largest by planned enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 12 of the 14 other live ones, and was the 65th registered.
155 studies on the registry are indexed under End Stage Liver Disease; 31 are open to participants now.
Browse End Stage Liver Disease studies →9 of the 66 studies in End Stage Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Elizabeth C. Verna · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Children's Hospital Medical Center, Cincinnati · Sites in United States
LyGenesis, Inc. · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 End Stage Liver Disease studies recruiting now, 14 (67%) set no upper age limit and 6 (29%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 1 · Phase 4 5
First in 2000; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 66 across 95 interventional studies indexed under End Stage Liver Disease.
Median enrollment 64 across the 48 interventional studies, 132 across the 18 observational. Of the 43 that completed or were terminated, 13 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 66 have an industry lead sponsor. The 10 most frequent:
University of California, Los Angeles is the lead sponsor of 1,172 studies on the registry; 195 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.
University of California, Los Angeles has 3 studies filed under End Stage Liver Disease — fewer than ten, so there is no comparison to draw.
8 of the studies in End Stage Liver Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03803423Johns Hopkins UniversityDissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors | 2026-11-27 |
| NCT04592744University of California, Los AngelesAngiotensin 2 for AKI After OLT | 2026-12 |
| NCT05998330Massachusetts General HospitalLiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease | 2026-12-01 |
| NCT06136221University of PennsylvaniaTesting LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease | 2026-12-30 |
| NCT05205954Massachusetts General HospitalHepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 66 studies in End Stage Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed Tolerance" approach, achieving success in numerous kidney recipients now living drug-free. The process uses a conditioning regimen followed by donor stem cell infusion to retrain the immune system to accept the liver as "self."
This study seeks to determine if patients with a pre-existing, well-functioning liver transplant from an HLA-matched living donor can be withdrawn from maintenance immunosuppressive medications without compromising allograft function through hematopoietic stem and progenitor cell (HSPC) infusion from the same donor. HSPC infusion will be preceded by a conditioning regimen of total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (rATG) that takes course over two weeks, with HSPC infusion being on the final day. This entire protocol will take place in the outpatient setting.
At serial time points, (1) graft function will be monitored, (2) chimerism will be measured in recipient whole blood and white blood cell subsets, and (3) protocol biopsies of the graft will be obtained. An attempt will be made to discontinue tacrolimus. Weaning of tacrolimus will begin at 6 months with a goal of discontinuation by 10-12 months as long as the following conditions are met: (1) donor chimerism is detectable for at least 180 days after HSPC infusion, (2) stable graft function (defined as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), and total bilirubin (TBil) levels each ≤ 2.0 × the upper limit of normal) is maintained without clinical or biopsy-determined rejection episodes, and (3) there is no evidence of graft-versus-host disease . HSPC infusion will consist of a target dose of 10 x106 CD34+ cells/kg and 5 x106 CD3+ cells/kg with the goal of achieving durable mixed chimerism.
Immunological tolerance through combined solid organ and HSPC transplant has been demonstrated at a few centers of excellence within the United States, including UCLA. The aim of these protocols is to liberate patients from lifelong immunosuppression. Thus far, protocols have been largely limited to HLA-matched donor recipient pairs undergoing simultaneous kidney and HSPC transplant from the same donor. In all protocols, the recipient undergoes a conditioning regimen to facilitate HSPC engraftment. At UCLA, our protocol employs a conditioning regimen of TLI and ATG. We are the first center to demonstrate the feasibility of retroactive immune tolerance, where a patient with a pre-existing fully HLA-matched kidney transplant underwent HSPC infusion following a conditioning regimen of TLI and ATG over one year after the kidney transplant surgery and successfully achieved durable mixed chimerism and tolerance, allowing permanent discontinuation of immunosuppressants - a process called "delayed tolerance."
Though the liver has intrinsic tolerogenic properties, tolerance protocols for liver are largely limited by the medical and logistical demands of recovering from liver transplant. As we have demonstrated in our single center experience, delayed tolerance has potential to be a reproducible strategy to permanently discontinue immunosuppressants in recipients who receive HSPC transplant months to years after transplant surgery. As such, recipients of HLA-matched living-donor liver transplants who have recovered from their surgery may benefit from protocols to establish tolerance and liberate them from lifelong immunosuppression.
Recipient Inclusion Criteria:
Recipient Exclusion Criteria:
History of active within the past 5 years except for:
viremia from EBV, CMV, or PCR test within the past 3 months.
Active hepatobiliary and pancreatic diseases:
Donor Inclusion Criteria:
Must meet the following criteria for HSPC donation:
Donor exclusion criteria:
History of active malignancy within the past 5 years except for:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult recipients with a pre-existing, well-functioning HLA-matched living-donor liver transplant from the same donor will undergo outpatient conditioning with total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (rATG), followed by infusion of mobilized donor hematopoietic stem and progenitor cells (separate CD34+ and CD3+ fractions). After HSPC infusion, participants will be monitored for donor chimerism, graft function, rejection, and GVHD, and will undergo a structured taper of maintenance immunosuppression with the goal of complete withdrawal if donor chimerism is present and protocol criteria are met.
Biological: Donor Hematopoietic Stem and Progenitor Cell Infusion
Participants with a pre-existing, well-functioning HLA-matched living-donor liver transplant from the same donor will receive a delayed infusion of donor-derived hematopoietic stem and progenitor cells (HSPCs). Donors undergo mobilization and apheresis to collect peripheral blood stem cells, which are processed to generate a CD34+ cell product with an accompanying defined CD3+ T-cell dose. Recipients receive outpatient conditioning with total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (rATG) prior to infusion. The goal of the intervention is to induce tolerance by achieving durable mixed chimerism and enable structured withdrawal of maintenance immunosuppression.
Also known as: Donor HSPC Infusion
Percentage of subjects weaned off liver transplant immunosuppressants at 12 months after HSPC infusion
The percentage of subjects who successfully discontinue all liver transplant immunosuppressant medications at 12 months after HSPC infusion.
Time frame: 12 months post-HSPC infusion.
Liver graft rejection within 48 months post-HSPC infusion
Percentage of subjects with liver graft rejection within 48 months after HSPC infusion, defined as: 1. meeting Banff criteria for rejection on biopsy obtained to confirm clinical suspicion, or 2. clinical suspicion of rejection with response to corticosteroids when biopsy is contraindicated or declined.
Time frame: Up to 48 months post-HSPC infusion.
Graft failure
Percentage of subjects with graft failure as determined by re-listing for liver transplantation and/or re-transplantation.
Time frame: Up to 48 months post-HSPC infusion.
Incidence of GVHD
Incidence of graft-versus-host disease (GVHD) defined as grade ≥2 acute GVHD or score ≥2 chronic GVHD.
Time frame: Up to 48 months post-HSPC infusion.
Chimerism persistence
Percentage of subjects with detectable donor-recipient chimerism for at least 180 days within the first 12 months after HSPC infusion, and at 12, 24, 36, and 48 months.
Time frame: 12, 24, 36, and 48 months post-HSPC infusion.
Incidence of acute or chronic GVHD (detailed)
Percentage of subjects that experienced acute or chronic GVHD, diagnosed clinically and/or by biopsy of the affected organ.
Time frame: Up to 48 months post-HSPC infusion
Liver function
Percentage of subjects with normal liver function tests (AST, ALT, ALP, TBil, and GGT each ≤ 2× upper limit of normal) at 12, 24, 36, and 48 months.
Time frame: 12, 24, 36, and 48 months post-HSPC infusion.
Infection burden
Mean number of bacterial, fungal, and viral infections per subject at 12, 24, 36, and 48 months.
Time frame: 12, 24, 36, and 48 months post-HSPC infusion.
Change in medication use for metabolic syndrome
Percentage and average change in dosing of subjects requiring medications for hypertension, diabetes, and hyperlipidemia at Months 6, 12, 24, 36, and 48.
Time frame: 6, 12, 24, 36, and 48 months post-HSPC infusion.
Quality of Life as Assessed by Change from Baseline in PROMIS-29 Profile v2.1 Through Month 48
The Patient-Reported Outcomes Measurement Information System 29-Item Profile v2.1 (PROMIS-29 Profile v2.1) is a validated 29-item patient-reported outcome measure assessing physical, mental, and social health in liver transplant recipients. Domains include physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and social roles.
Time frame: Baseline, Day 14, and Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 36, and 48 post-HSPC infusion
Quality of Life as Assessed by Change from Baseline in MTSOSD-R 59 Through Month 48
Modified Transplant Symptom Occurrence and Symptom Distress Scale - Revised (MTSOSD-R 59) is a transplant-specific symptom inventory that assesses symptom occurrence and associated distress in immunosuppressed liver transplant recipients across multiple domains.
Time frame: Baseline, Day 14, and Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 36, and 48 post-HSPC infusion
Quality of Life as Assessed by Change from Baseline in pLTQ Through Month 48
Post-Liver Transplant Quality of Life Instrument (pLTQ) is a liver transplant-specific quality-of-life instrument assessing physical, psychological, and social functioning domains relevant to long-term transplant outcomes.
Time frame: Baseline, and Months 6, 12, 24, 36, and 48 post-HSPC infusion
Plan to share: No — IPD will not be shared because this is a Phase I, single-site study involving transplant recipients and their living donors, where data elements such as HLA high-resolution typing, chimerism profiles, and longitudinal graft function measurements are inherently identifiable. Sharing raw IPD would pose a significant re-identification risk and is not permitted under the study's IND, IRB approval, or institutional policies for early-phase cellular therapy trials. Aggregate, de-identified results will be disseminated through scientific publications and presentations, but participant-level datasets will not be made publicly available.
Started Feb 2026 (actual). Primary completion is estimated for Jan 2029, 35 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Los Angeles →